Full-Time

Senior/Staff Software Engineer

Full Stack

Confirmed live in the last 24 hours

Dyno Therapeutics

Dyno Therapeutics

51-200 employees

Develops AI-optimized AAV vectors for gene therapy

AI & Machine Learning
Biotechnology
Healthcare

Mid, Senior

Belmont, MA, USA

Strong preference for candidates based in NYC or Greater Boston areas for occasional in-person engagements.

Category
Full-Stack Engineering
Software Engineering
Required Skills
Python
React.js
Vue.js
FastAPI
Flask
Django
Requirements
  • Strong programming and system design fundamentals with 4+ years of experience with full stack development.
  • Developing frontend applications using modern frameworks such as React (or other comparable frameworks such as Vue.js, Svelte, etc.).
  • Backend system design & development from DB to API.
  • Experience working cross-team to communicate with both technical and business stakeholders as well as customers.
  • Experience with Python backend development (examples include: Django, FastAPI, Flask, etc.).
  • Demonstrated examples of applying product taste.
  • Excitement about (but not necessarily experience with) building products that let scientists do more, faster.
  • Experience building on top of ML models and/or LLMs.
  • Have built products in the 0-1 stage.
  • Even limited experience managing cloud deployments and environments.
  • Excited to learn about bio/gene therapy (no experience necessary).
Responsibilities
  • Lead end-to-end development of new products for genetic sequence design within the ML Products team.
  • Iterating on ideas and prototypes and then prioritizing the path to an MVP.
  • Develop and disseminate best practices for repeatable and scalable end to end product development.
  • Collaborate with team members ranging from engineers, computational biologists, ML researchers, and biologists to come up with and build great products.
  • Mentor and teach other engineers on the team.

Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, and Dyno's AI technology enhances their design and optimization, potentially increasing the effectiveness of gene therapies. The company collaborates with major pharmaceutical and biotech firms, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike its competitors, Dyno leverages proprietary AI technology to streamline the creation of AAV vectors, which sets it apart in the biotech field. The goal of Dyno Therapeutics is to improve gene therapy outcomes through optimized delivery systems, ultimately contributing to better treatment options for patients.

Company Stage

Series A

Total Funding

$106M

Headquarters

Watertown, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

-13%

1 year growth

-13%

2 year growth

-4%
Simplify Jobs

Simplify's Take

What believers are saying

  • Dyno's AI-driven approach has led to significant breakthroughs, such as an 80-fold increase in eye delivery efficiency and a 100-fold increase in brain delivery efficiency.
  • Collaborations with industry giants like NVIDIA enhance Dyno's capabilities in biological sequence design, promising accelerated innovation and market growth.
  • Recognition from prestigious organizations, including being named Emerging Company of the Year by the New England Venture Capital Association, underscores Dyno's industry leadership and growth potential.

What critics are saying

  • The high cost of gene therapies remains a barrier, and while Dyno aims to reduce these costs, achieving this goal is uncertain.
  • The rapid pace of AI and biotech advancements means that Dyno must continuously innovate to stay ahead of competitors.

What makes Dyno Therapeutics unique

  • Dyno Therapeutics leverages AI to design optimized AAV vectors, setting it apart from traditional gene therapy companies that rely on conventional methods.
  • Their proprietary AI technology, combined with high-throughput experimentation, allows for the rapid development of highly efficient capsids, a significant advantage over competitors.
  • Partnerships with leading pharmaceutical companies like Astellas, Roche, and Novartis validate Dyno's innovative approach and provide a strong market position.

Help us improve and share your feedback! Did you find this helpful?